Mark Ledoux, MD
Neurology · Memphis, TNNPI 1407813439
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $273,699 of the $351,587 with a category attached, or 77.8%. 28 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 44.9% of the total. Reporting peaked in 2019 at $89,635 and has fallen 51.0% since, to $43,941 in 2025. Among neurology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 695 payments — averaging $505.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$158K
- Amneal Pharmaceuticals LLC$69K
- MDD US Operations, LLC$40K
- Kyowa Kirin, Inc.$32K
- Acadia Pharmaceuticals Inc$28K
- Acorda Therapeutics, Inc$17K
- plus $6K from 22 others
Across 181 payments — averaging $4765.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$540K
- UCB SA$116K
- AbbVie$88K
- Amylyx Pharmaceuticals, Inc.$55K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$37K
- Teva Pharmaceuticals USA, Inc.$22K
- plus $5K from 2 others
What the payments were for
- Consulting fees$50,57314%
- Speaking & faculty fees$273,69978%
- Travel & lodging$15,6044%
- Food & beverage$9,9303%
- Education$1,7811%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 327 | $157,900 |
| Amneal Pharmaceuticals LLC | 72 | $69,402 |
| MDD US Operations, LLC | 95 | $40,124 |
| Kyowa Kirin, Inc. | 22 | $32,288 |
| Acadia Pharmaceuticals Inc | 65 | $28,447 |
| Acorda Therapeutics, Inc | 23 | $17,030 |
| Neurocrine Biosciences, Inc. | 7 | $3,727 |
| Otsuka America Pharmaceutical, Inc. | 3 | $1,550 |
| AstraZeneca | 7 | $191 |
| Medtronic(2 entities) | 6 | $126 |
| Sunovion Pharmaceuticals Inc. | 11 | $124 |
| EMD Serono, Inc. | 26 | $123 |
| Supernus Pharmaceuticals, Inc. | 5 | $86 |
| AbbVie(2 entities) | 5 | $80 |
| Lundbeck LLC | 3 | $68 |
| Avanir Pharmaceuticals, Inc. | 4 | $59 |
| Novartis | 3 | $50 |
| Biogen | 1 | $37 |
| Merz Pharmaceuticals, LLC | 1 | $31 |
| Lilly USA, LLC | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
| GE HealthCare | 1 | $17 |
| Adamas Pharmaceuticals, Inc. | 1 | $17 |
| Abbott | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Revance Therapeutics, Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$351,587 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 268 | $2,260,831 |
| RytaryCarbidopa/Levodopa | 462 | $645,834 |
| NuplazidPimavanserin Tartrate | 86 | $556,815 |
| AustedoDeutetrabenazine | 47 | $488,286 |
| GocovriAmantadine Hcl | 32 | $109,616 |
| InbrijaLevodopa | 16 | $92,456 |
| Droxidopa | 32 | $91,411 |
| Rasagiline Mesylate | 513 | $75,634 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 142 | $33,106 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 863 | $28,050 |
| Entacapone | 96 | $22,030 |
| NeuproRotigotine | 18 | $18,912 |
| Aripiprazole | 11 | $16,968 |
| Carbidopa | 33 | $13,695 |
| MyrbetriqMirabegron | 15 | $12,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $157,900 | $2,749,117315 claims |
| Amneal Pharmaceuticals LLCRytary | $69,402 | $645,834462 claims |
| Acadia Pharmaceuticals IncNuplazid | $28,447 | $556,81586 claims |
| MDD US Operations, LLCGocovri | $40,124 | $109,61632 claims |
| Acorda Therapeutics, IncInbrija | $17,030 | $92,45616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 neurology providers in Tennessee.
Other neurology in Memphis
- Lucas ElijovichMemphis$415K
- Khalid AlsherbiniMemphis$249K
- Andrei AlexandrovMemphis$225K
- Tulio BertoriniMemphis$160K
- Rozita KhaliliMemphis$91K
- Michael LevinMemphis$47K
- Michael JacewiczMemphis$33K
- James WangMemphis$27K
- Samuel HunterSpring Hill$676K
- Harold MosesNashville$438K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.